research article link, page-4

Well the key then is to produce some drugs that work using the identified mode of action. I suspect bit could market itself as an R&D lab but most pharma would prefer to see some tangible substances that can hit the market. The question you identified is whether bit225 is the best substance for the job as plucked from its library and may say it works but we may have better ones to create based on what has been identified from trials and the way bit 225 works? Presumably they need to convince pharma of the science and that they have some potency in their library to move it into treatment combinations. I am a little lost as to their exact strategy.